IDEXX Laboratories, Inc. vs Ralph Lauren Corp — how do they compare? IDEXX Laboratories, Inc. trades at $518.35 (market cap $40.43B), while Ralph Lauren Corp trades at $368.98 (market cap $21.89B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Ralph Lauren Corp pays a 1.09% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Ralph Lauren Corp for 84 Days on average.
| IDXX | RL | |
|---|---|---|
Market Cap | $40.43B | $21.89B |
Volume | 692,164 | 481,617 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $414.25 |
52-Week Low | $504.70 | $309.29 |
Typical Hold Time | 46 Days | 84 Days |
Enterprise Value | $41.32B | $22.95B |
Dividend Yield | — | 1.09% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Ralph Lauren (RL) trades at $361.14, down 2.04% on the day, amid a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $7.08 billion and $743 million in 2025, respectively, while profitability metrics like a 70.27% gross margin and 37.54% ROE highlight operational strength. Analyst sentiment remains bullish with a consensus price target of $456.67, though technical indicators show near-term resistance at $363.
The outlook for RL is positive based on fundamental growth and analyst support, but investors face risks from market volatility and execution challenges. The stock's current valuation at a P/E of 23.15 appears reasonable given earnings momentum, yet competitive pressures and macroeconomic factors could limit upside. Institutional confidence is high, with 66.67% of analysts rating it a buy, suggesting potential for appreciation if the company maintains its earnings trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →